Japan's unsettled drug payments improve

17 November 2008

Japan's Ministry of Health, Labor and Welfare recently reported to the Committee on the Improvement of Prescription Drug Distribution that unsettled payments between medical facilities, including dispensing pharmacies and drug wholesalers, have been improved following efforts by stakeholders last fall to achieve this.

In fall 2007, the Committee issued "an emergency proposal to improve prescription drug distribution" based on "the points to consider" as far as what drug manufacturers, wholesalers and medical facilities should actually implement to improve the current problems with distribution, including unsettled payments, provisional shipments of drugs, rebates and lump-sum bulk buying (Marketletter November 5, 2007).

According to the Ministry's survey, 57.2% of payments in total medical facilities were settled in October 2006 but, when the previous National Health Insurance drug price revision was implemented, this increased to 70.9% in September 2008. By facility, hospitals with over 200 beds, other hospitals and clinics rose from 30.6%, 60.7% and 84.8% to 46.7%, 66.8% and 88.6%, respectively. Over this timeframe, chain pharmacies with over 20 outlets rose from 14.4% to 71.7%, confirming the efforts to improve the situation by the chain pharmacy-related groups. Other pharmacies increased from 62.2% to 77.2%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight